This observational study aims to find the best combination of biological markers (biomarkers) and health information to help detect lung cancer early, confirm its presence, improve treatment, and reduce the chance of it coming back. Researchers will collect blood samples and health data from people with lung nodules (small growths in the lung) that doctors suspect might be cancer. These samples will be collected before any invasive tests or treatments begin. The study will look at how accurate different biomarkers are and how easy they are to collect. The goal is to improve methods for identifying lung cancer. You may be able to join if you are 18 or older, have a lung nodule at least 5mm wide that hasn't been biopsied or surgically removed, and your doctor thinks there's a greater than 5% chance it could be cancer. The study plans to enroll 2000 participants, but its current status is unclear.

Study design

This is an observational study planning to enroll 2000 participants. It is designed to determine the optimal combination of biomarkers and clinical data for lung cancer detection and treatment.

What's involved

You would provide peripheral venous blood and clinical data. These samples and data will be collected before any invasive diagnosis or treatment is started.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, test performance, will be measured two years from the final case enrollment. Results will not be reported to treating physicians and will not alter care of the patient.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.